Pentostatin/Cyclophosphamide with or without Rituximab: an effective regimen for patients with Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma
Background - Pentostatin has demonstrated significant activity as a single agent in patients with low-grade B-cell and T-cell lymphomas and is less myelosuppressive than other purine analogues. - Patients and Methods - We conducted a phase II trial with the combination regimen of PC-R (pentostatin/c...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
[September 2005]
|
| In: |
Clinical lymphoma & myeloma
Year: 2005, Volume: 6, Issue: 2, Pages: 131-135 |
| ISSN: | 1938-0712 |
| DOI: | 10.3816/CLM.2005.n.039 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3816/CLM.2005.n.039 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1557919011703808 
|
| Author Notes: | Manfred Hensel, Matthias Villalobos, Martin Kornacker, Fatime Krasniqi, Anthony D. Ho |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1780189184 | ||
| 003 | DE-627 | ||
| 005 | 20230427104144.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211203s2005 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3816/CLM.2005.n.039 |2 doi | |
| 035 | |a (DE-627)1780189184 | ||
| 035 | |a (DE-599)KXP1780189184 | ||
| 035 | |a (OCoLC)1341423946 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hensel, Manfred |d 1964- |e VerfasserIn |0 (DE-588)1065849729 |0 (DE-627)816878307 |0 (DE-576)425541908 |4 aut | |
| 245 | 1 | 0 | |a Pentostatin/Cyclophosphamide with or without Rituximab |b an effective regimen for patients with Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma |c Manfred Hensel, Matthias Villalobos, Martin Kornacker, Fatime Krasniqi, Anthony D. Ho |
| 264 | 1 | |c [September 2005] | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Elektronische Reproduktion der Druck-Ausgabe | ||
| 500 | |a Gesehen am 03.12.2021 | ||
| 520 | |a Background - Pentostatin has demonstrated significant activity as a single agent in patients with low-grade B-cell and T-cell lymphomas and is less myelosuppressive than other purine analogues. - Patients and Methods - We conducted a phase II trial with the combination regimen of PC-R (pentostatin/cyclophosphamide with or without rituximab) in 14 patients with Waldenström's macroglobulinemia (WM) and 3 patients with lymphoplasmacytic lymphoma (LL) without monoclonal serum immunoglobulin M (IgM), followed by a maintenance regimen with rituximab (375 mg/m2 every 3 months) for patients exhibiting a complete response (CR) or a partial response (PR) after 4-6 cycles. Nine patients were untreated, and 8 had been previously treated with 1-3 regimens. The first 9 patients received PC therapy (pentostatin 4 mg/m2 plus cyclophosphamide 600 mg/m2), and 8 patients received the same combination with rituximab 375 mg/m2 on day 1. Cycles were repeated every 3 weeks. - Results - An objective tumor response after PC and PC-R was confirmed in 11 of 17 evaluable patients (64.7%), with 2 CRs (11.7%) and 9 PRs (52.9%). In patients who received rituximab (n = 13) simultaneously or subsequently, the overall response rate was 76.9%. Grade 2/3 nausea and grade 2 vomiting was generally mild based on World Health Organization criteria. Grade 3 hematologic toxicity occurred after 9 of 49 cycles (18.3%), and grade 4 toxicity occurred after 2 cycles (4%). Ten patients were subsequently treated with rituximab every 3 months for 2-9 cycles to date (median, 4 cycles). No patients have had disease relapse to date, and all exhibited stable IgM serum levels. In 3 patients with a PR after completion of chemotherapy, remission has improved further, with normalization of the IgM level in 1 patient and another patient exhibiting a CR. - Conclusion - Our data indicate that PC-R is safe and highly effective in patients with WM. Maintenance therapy with rituximab for WM as a single infusion every 3 months can be administered safely and can improve remission status. | ||
| 650 | 4 | |a Antibody therapy | |
| 650 | 4 | |a Immunocytoma | |
| 650 | 4 | |a Maintenance treatment | |
| 650 | 4 | |a Purine analogues | |
| 700 | 1 | |a Villalobos Bollen, Matthias Americo |d 1974- |e VerfasserIn |0 (DE-588)1078644306 |0 (DE-627)839010133 |0 (DE-576)451580516 |4 aut | |
| 700 | 1 | |a Kornacker, Martin |d 1966- |e VerfasserIn |0 (DE-588)11573774X |0 (DE-627)691553858 |0 (DE-576)290048524 |4 aut | |
| 700 | 1 | |a Krasniqi, Fatime |e VerfasserIn |0 (DE-588)131350005 |0 (DE-627)50796408X |0 (DE-576)298422662 |4 aut | |
| 700 | 1 | |a Ho, Anthony Dick |d 1948- |e VerfasserIn |0 (DE-588)108692477 |0 (DE-627)504904205 |0 (DE-576)19010466X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical lymphoma & myeloma |d Dallas, Tex. : Cancer Information Group, 2005 |g 6(2005), 2, Seite 131-135 |h Online-Ressource |w (DE-627)491438222 |w (DE-600)2193618-3 |w (DE-576)377665541 |x 1938-0712 |7 nnas |a Pentostatin/Cyclophosphamide with or without Rituximab an effective regimen for patients with Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma |
| 773 | 1 | 8 | |g volume:6 |g year:2005 |g number:2 |g pages:131-135 |g extent:5 |a Pentostatin/Cyclophosphamide with or without Rituximab an effective regimen for patients with Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma |
| 856 | 4 | 0 | |u https://doi.org/10.3816/CLM.2005.n.039 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S1557919011703808 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20211203 | ||
| 993 | |a Article | ||
| 994 | |a 2005 | ||
| 998 | |g 108692477 |a Ho, Anthony Dick |m 108692477:Ho, Anthony Dick |d 910000 |d 910100 |e 910000PH108692477 |e 910100PH108692477 |k 0/910000/ |k 1/910000/910100/ |p 5 |y j | ||
| 998 | |g 131350005 |a Krasniqi, Fatime |m 131350005:Krasniqi, Fatime |d 50000 |e 50000PK131350005 |k 0/50000/ |p 4 | ||
| 998 | |g 11573774X |a Kornacker, Martin |m 11573774X:Kornacker, Martin |d 910000 |d 910100 |e 910000PK11573774X |e 910100PK11573774X |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 998 | |g 1078644306 |a Villalobos Bollen, Matthias Americo |m 1078644306:Villalobos Bollen, Matthias Americo |d 910000 |d 910100 |e 910000PV1078644306 |e 910100PV1078644306 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 1065849729 |a Hensel, Manfred |m 1065849729:Hensel, Manfred |d 910000 |d 910100 |e 910000PH1065849729 |e 910100PH1065849729 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1780189184 |e 4013452634 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"title":[{"title":"Pentostatin/Cyclophosphamide with or without Rituximab","subtitle":"an effective regimen for patients with Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma","title_sort":"Pentostatin/Cyclophosphamide with or without Rituximab"}],"recId":"1780189184","name":{"displayForm":["Manfred Hensel, Matthias Villalobos, Martin Kornacker, Fatime Krasniqi, Anthony D. Ho"]},"origin":[{"dateIssuedDisp":"[September 2005]","dateIssuedKey":"2005"}],"person":[{"display":"Hensel, Manfred","given":"Manfred","family":"Hensel","role":"aut"},{"family":"Villalobos Bollen","given":"Matthias Americo","display":"Villalobos Bollen, Matthias Americo","role":"aut"},{"family":"Kornacker","given":"Martin","display":"Kornacker, Martin","role":"aut"},{"given":"Fatime","display":"Krasniqi, Fatime","family":"Krasniqi","role":"aut"},{"given":"Anthony Dick","display":"Ho, Anthony Dick","family":"Ho","role":"aut"}],"relHost":[{"recId":"491438222","disp":"Pentostatin/Cyclophosphamide with or without Rituximab an effective regimen for patients with Waldenström's macroglobulinemia/lymphoplasmacytic lymphomaClinical lymphoma & myeloma","language":["eng"],"titleAlt":[{"title":"Lymphoma"},{"title":"Clinical lymphoma and myeloma"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["6.2005,2 - 9.2009"],"origin":[{"dateIssuedDisp":"2005-2009","publisher":"Cancer Information Group","publisherPlace":"Dallas, Tex.","dateIssuedKey":"2005"}],"title":[{"title":"Clinical lymphoma & myeloma","title_sort":"Clinical lymphoma & myeloma"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"year":"2005","pages":"131-135","text":"6(2005), 2, Seite 131-135","volume":"6","extent":"5","issue":"2"},"id":{"issn":["1938-0712"],"zdb":["2193618-3"],"eki":["491438222"]},"note":["Gesehen am 12.03.24"]}],"note":["Elektronische Reproduktion der Druck-Ausgabe","Gesehen am 03.12.2021"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.3816/CLM.2005.n.039"],"eki":["1780189184"]},"physDesc":[{"extent":"5 S."}]} | ||
| SRT | |a HENSELMANFPENTOSTATI2005 | ||